Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a stock to watch today. At current price of $24.71, the shares have already added 1.02 points (4.31% higher) from its previous close of $23.69. The stock sets an active trading volume day with a reported 210721 contracts so far this session. VYGR shares had a relatively better volume day versus average trading capacity of 521.31 thousand shares, but with a 31.17 million float and a -3.27% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for VYGR stock indicates that the average analyst price target is $26.17 per share. This means the stock has a potential increase of 5.91% from where the VYGR share price has been trading recently which is between $23.385 and $24.16. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $17.
The shorts are running away from Voyager Therapeutics, Inc. (VYGR) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a drop in short interest in VYGR shares. While short interest still represents only 6.14% of VYGR’s float, the number of shares shorted have fallen by -207958. The number of shares shorted fell to 1706387 shares, down from 1914345 shares during the preceding fortnight. With average daily trading volumes at 336905 shares, days to cover increased to about 3.927329 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates” and dated May 07, 2019.
During the recent trading session for Voyager Therapeutics, Inc. (NASDAQ:VYGR), the company witnessed their stock rise $0.85 over a week and surge $5.28 from the price 20 days ago. When compared to their established 52-week high of $25.74, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 05/16/19. The recent low of $7.76 stood for a -2.14% since 01/24/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.68 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Voyager Therapeutics, Inc., the two-week RSI stands at 64.13. This figure suggests that VYGR stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current VYGR readings is similarly very revealing as it has a stochastic reading of 70.49% at this stage. This figure means that VYGR share price today is being oversold.
Technical chart claims that Voyager Therapeutics, Inc. (VYGR) would settle between $24.1/share to $24.52/share level. However, if the stock price goes below the $23.33 mark, then the market for Voyager Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $22.97 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.14. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Raymond James raised their recommendation on shares of VYGR from Outperform to Strong Buy in their opinion released on November 15. BTIG Research, analysts launched coverage of Voyager Therapeutics, Inc. (NASDAQ:VYGR) stock with a Buy recommendation, according to their flash note issued to investors on September 10. Analysts at Morgan Stanley lowered the stock to a Equal-Weight call from its previous Overweight recommendation, in a research note that dated back to September 10.
VYGR equity has an average rating of 1.75, with the figure leaning towards a bullish end. 12 analysts who tracked the company were contacted by Reuters. Amongst them, 3 rated the stock as a hold while the remaining 9 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 9 analysts rated Voyager Therapeutics, Inc. (NASDAQ:VYGR) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, VYGR stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 67.04 while for the average stock in the same group, the multiple is 49.5.
Voyager Therapeutics, Inc. (VYGR)’s current-quarter revenues are projected to climb by nearly 45.35% to hit $3.75 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 229.98% from $7.62 million to a noteworthy $25.14 million. At the other end of the current quarter income statement, Voyager Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly -3.75% to hit $-0.83 per share. For the fiscal year, VYGR’s earnings are projected to climb by roughly -0.73% to hit $-2.77 per share.